Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noninferiority Study of CT-P13 (Remsima) vs Remicade in Active Crohn's Disease
2013-004497-10Phase 3Completed
- Sponsor
- Celltrion
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of infliximab in Crohn's disease (2 arms), sponsored by Celltrion. Started May 2014; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2013-004497-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004497-10.